Johnson & JohnsonvsRapport Therapeutics

JNJ and RAPP stock compared: price, dividend, valuation and results, from SEC filings.

RAPP

Rapport Therapeutics, Inc.

$23.76

Value $1.1B

-4.27%
RAPP's page

Johnson & Johnson (JNJ) has a market value of $672B and Rapport Therapeutics (RAPP) $1.1B. Over the last year, with dividends, JNJ moved +45.4% and RAPP -2.5%. Dividend yield: JNJ 1.89%, RAPP none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$672B

    RAPP$1.1B

    JNJ is 591 times RAPP

  • Revenue, 12 months

    JNJ$99.3B

    RAPP–

  • Net income, 12 months

    JNJ$16.1B

    RAPP-$150M

  • Operating margin

    JNJ–

    RAPP–

  • ROIC

    JNJ12.4%

    RAPP-20.4%

    32.8 points apart

  • P/E

    JNJ41.7

    RAPP–

  • Dividend yield

    JNJ1.9%

    RAPP0.0%

    1.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+45.4%

RAPP-2.5%

100150200DecFebAprJunAugOct
Returns by period
PeriodJNJWith dividendsRAPPWith dividends
1 year since November 14, 2025+45.4%Price +42.2%-2.5%Price -2.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonRAPPRapport Therapeutics

Valuation

JNJRAPP
Valuation
Price$278.70$23.76
Market value$672B$1.1B
Enterprise value (EV)$699B$741M
P/E41.7–
P/E, 5-year median21.9–
P/B8.22.9
EV/EBIT39.4–
Free cash flow yield3.1%–

Results and growth

JNJRAPP
Results and growth
Revenue, 12 months$99.3B–
Net income, 12 months$16.1B-$150M
Free cash flow, 12 months$20.6B-$121M
Earnings per share, 12 months$6.59-$3.16
Revenue growth, year on year6.1%–
Revenue growth a year, past+2.7%over 5 years–
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJRAPP
Margins and returns on capital
Gross margin67.6%–
Operating margin––
Net margin16.2%–
ROIC12.4%-20.4%
ROE19.7%-33.0%

Balance sheet

JNJRAPP
Balance sheet
Cash$17.2B$395M
Total debt$44.7B$9.4M
Net debt / EBITDA1.1–
Interest cover18.0×–

Dividends and buybacks

JNJRAPP
Dividends and buybacks
Dividend yield1.9%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%0.0%
Shareholder yield2.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or RAPP

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Rapport Therapeutics?

By market value, Johnson & Johnson ($672B) is about 591.5 times Rapport Therapeutics ($1.1B), at today's prices.

How did JNJ and RAPP stock do over the last 1 years?

Since November 14, 2025, JNJ's price moved +42.2% and RAPP's -2.5%. With dividends: JNJ +45.4% (+45.4% a year), RAPP -2.5% (-2.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or RAPP?

The dividend yield at today's price is 1.89% for Johnson & Johnson and none for Rapport Therapeutics. Over the last twelve months they paid $5.28 and – per share.

Which is the better investment, Johnson & Johnson or Rapport Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.